{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:13:30Z","timestamp":1791461610930,"version":"4.3.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiotoxicity is a relatively frequent and potentially serious side effect of anticancer treatments, particularly anthracyclines and trastuzumab, widely used in the treatment of breast cancer. The increase in cancer survivors has generated a growing interest in the prevention of cardiotoxicity. Although early studies suggested an overall benefit on cardiac function with the use of ACE inhibitors (ACEIs) and beta blockers (BBs), more recent randomized trials have demonstrated little or no effect of pharmacological interventions. Even the various meta-analyses conducted in this area have provided weak results in favour of cardioprotective therapies for which the benefit would not always justify the risk of developing side effects. Given the incompleteness of the evidence, there is no clear consensus on which patients should initiate cardioprotective therapy. As recommended in the new guidelines of the European Society of Cardiology, risk stratification before treatment is crucial to identify high-risk patients who would benefit most from the use of cardioprotective therapy. Randomized trials are currently underway to evaluate other therapeutic strategies such as sacubitril\/valsartan, and the possibility of using gliflozins in the future cannot be excluded. However, rigorous control and treatment of risk factors remain the primary focus in the management of these patients.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad062","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:58:25Z","timestamp":1682099905000},"page":"B25-B27","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?"],"prefix":"10.1093","volume":"25","author":[{"given":"Irma","family":"Bisceglia","sequence":"first","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Mistrulli","sequence":"additional","affiliation":[{"name":"Cardiology Department, Sapienza University of Rome, Sant'Andrea Hospital , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cartoni","sequence":"additional","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Matera","sequence":"additional","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Petrolati","sequence":"additional","affiliation":[{"name":"Department of Cardiosciences, A.O. San Camillo-Forlanini , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Canale","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda USL Toscana nord-ovest, Versilia Hospital , Lido di Camaiore , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117451384700_suad062-B1","doi-asserted-by":"crossref","first-page":"e 015327","DOI":"10.1161\/JAHA.119.015327","article-title":"The role of angiotensin-converting enzyme inhibitors and \u03b2-blockers in primary prevention of cardiac dysfunction in breast cancer patients","volume":"9","author":"Brown","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023042117451384700_suad062-B2","author":"National Cancer Institute"},{"key":"2023042117451384700_suad062-B3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042117451384700_suad062-B4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2023042117451384700_suad062-B5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2023042117451384700_suad062-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2023042117451384700_suad062-B7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"2023042117451384700_suad062-B8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2(2 factorial, randomized, placebo controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2023042117451384700_suad062-B9","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"2023042117451384700_suad062-B10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: A randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"key":"2023042117451384700_suad062-B11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2023042117451384700_suad062-B12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the heart failure association-international cardio-oncology society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2023042117451384700_suad062-B13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"2023042117451384700_suad062-B14","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042117451384700_suad062-B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC Cardio Oncol"},{"key":"2023042117451384700_suad062-B16","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042117451384700_suad062-B17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/eurheartj\/ehab810","article-title":"Cardioprotection in breast cancer patients: one size fits all?","volume":"43","author":"Gulati","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042117451384700_suad062-B18","first-page":"33","article-title":"Rationale and design of the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B25\/50061090\/suad062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B25\/50061090\/suad062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:58:37Z","timestamp":1682099917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B25\/7135780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":18,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad062","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}